Copyright
©The Author(s) 2025.
World J Diabetes. Apr 15, 2025; 16(4): 102390
Published online Apr 15, 2025. doi: 10.4239/wjd.v16.i4.102390
Published online Apr 15, 2025. doi: 10.4239/wjd.v16.i4.102390
Figure 2 The putative mechanisms for cardiovascular protection associated with the use of sodium-glucose co-transporter 2 inhibitors.
DKA: Diabetes ketoacidosis; BP: Blood pressure; NEFA: Non-esterified fatty acids; SGLT2: Sodium-glucose co-transporter 2; HDL: High-density lipoprotein; TG: Triglycerides; CNS: Central nervous system; HbA1c: Glycated hemoglobin.
- Citation: Ganakumar V, Fernandez CJ, Pappachan JM. Antidiabetic combination therapy and cardiovascular outcomes: An evidence-based approach. World J Diabetes 2025; 16(4): 102390
- URL: https://www.wjgnet.com/1948-9358/full/v16/i4/102390.htm
- DOI: https://dx.doi.org/10.4239/wjd.v16.i4.102390